664 related articles for article (PubMed ID: 25316870)
1. Modeling the dynamics of oral poliovirus vaccine cessation.
Thompson KM; Duintjer Tebbens RJ
J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
[TBL] [Abstract][Full Text] [Related]
2. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
[TBL] [Abstract][Full Text] [Related]
3. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.
Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S412-23. PubMed ID: 25316863
[TBL] [Abstract][Full Text] [Related]
4. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
5. [Circulating vaccine-derived poliovirus type 2 outbreak in Democratic Republic of Congo 2011-2012].
Bazira L; Coulibaly T; Mayenga M; Ncharre C; Yogolelo R; Mbule A; Moudzeo H; Lwamba P; Mulumba AW; Cabore J
Bull Soc Pathol Exot; 2015 Oct; 108(4):235-41. PubMed ID: 26288132
[TBL] [Abstract][Full Text] [Related]
6. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
[TBL] [Abstract][Full Text] [Related]
7. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
[TBL] [Abstract][Full Text] [Related]
8. A developing country perspective on vaccine-associated paralytic poliomyelitis.
John TJ
Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
[TBL] [Abstract][Full Text] [Related]
9. Update on vaccine-derived polioviruses--worldwide, April 2011-June 2012.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Sep; 61():741-6. PubMed ID: 22992572
[TBL] [Abstract][Full Text] [Related]
10. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
[TBL] [Abstract][Full Text] [Related]
11. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
[TBL] [Abstract][Full Text] [Related]
12. Circulating vaccine-derived polioviruses: current state of knowledge.
Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
[TBL] [Abstract][Full Text] [Related]
13. Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017.
Jorba J; Diop OM; Iber J; Henderson E; Sutter RW; Wassilak SGF; Burns CC
MMWR Morb Mortal Wkly Rep; 2017 Nov; 66(43):1185-1191. PubMed ID: 29095803
[TBL] [Abstract][Full Text] [Related]
14. Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India.
Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S398-411. PubMed ID: 25316861
[TBL] [Abstract][Full Text] [Related]
15. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
[TBL] [Abstract][Full Text] [Related]
16. Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.
Diop OM; Burns CC; Sutter RW; Wassilak SG; Kew OM;
MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):640-6. PubMed ID: 26086635
[TBL] [Abstract][Full Text] [Related]
17. Transmission dynamics of oral polio vaccine viruses and vaccine-derived polioviruses on networks.
Kim JH; Rho SH
J Theor Biol; 2015 Jan; 364():266-74. PubMed ID: 25264265
[TBL] [Abstract][Full Text] [Related]
18. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
Duintjer Tebbens RJ; Thompson KM
BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
[TBL] [Abstract][Full Text] [Related]
19. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
Pliaka V; Kyriakopoulou Z; Markoulatos P
Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
[TBL] [Abstract][Full Text] [Related]
20. Notes from the Field: Circulating Vaccine-Derived Poliovirus Outbreaks - Five Countries, 2014-2015.
Morales M; Nnadi CD; Tangermann RH; Wassilak SG
MMWR Morb Mortal Wkly Rep; 2016 Feb; 65(5):128-9. PubMed ID: 26866942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
